共 9 条
- [1] Silent and prolonged Aspergillus DNAemia in oncohematological patients receiving antifungal prophylaxis: a new phenomenon with clinical implicationsBONE MARROW TRANSPLANTATION, 2011, 46 (07) : 1016 - 1017Meije, Y.Aguado, J. M.Cuenca-Estrella, M.
- [2] Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCTMICROORGANISMS, 2024, 12 (07)Gatti, MiloCampoli, CaterinaMuratore, EdoardoBelotti, TamaraMasetti, RiccardoLanari, MarcelloViale, PierluigiPea, Federico
- [3] Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxisMYCOSES, 2011, 54 : 1 - 6Karthaus, MeinolfHentrich, Marcus
- [4] Patterns of Infection in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia Receiving Azacitidine as Salvage Therapy. Implications for Primary Antifungal ProphylaxisCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (01): : 80 - 86Falantes, Jose F.Calderon, CristinaMarquez-Malaver, Francisco J.Aguilar-Guisado, ManuelaMartin-Pena, AlmudenaMartino, Maria L.Montero, IsabelGonzalez, JoseParody, RocioPerez-Simon, Jose A.Espigado, Ildefonso
- [5] Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids—clinical implication of primary prophylaxis using trimethoprim–sulfamethoxazoleArthritis Research & Therapy, 21Jun Won ParkJeffrey R. CurtisMin Jung KimHajeong LeeYeong Wook SongEun Bong Lee
- [6] Pneumocystis pneumonia in patients with rheumatic diseases receiving prolonged, non-high-dose steroids-clinical implication of primary prophylaxis using trimethoprim-sulfamethoxazoleARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)Park, Jun WonCurtis, Jeffrey R.Kim, Min JungLee, HajeongSong, Yeong WookLee, Eun Bong
- [7] The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in KoreaANNALS OF HEMATOLOGY, 2014, 93 (01) : 33 - 42Kim, Jin SeokCheong, June-WonKim, Yeo-KyeoungPark, JinnyMun, Yeung-ChulKang, Hye JinYi, Hyeon GyuLee, Je-HwanKim, Yang SooRyoo, Hun-MoKim, Sung-HyunKim, Ho YoungKim, Jin YoungLee, Dong-GunKim, Hoon-GuKim, HawkJoo, Young-DonMin, Yoo Hong
- [8] The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis: a multicenter, prospective, open-label, observational study in KoreaAnnals of Hematology, 2014, 93 : 33 - 42Jin Seok KimJune-Won CheongYeo-Kyeoung KimJinny ParkYeung-Chul MunHye Jin KangHyeon Gyu YiJe-Hwan LeeYang Soo KimHun-Mo RyooSung-Hyun KimHo Young KimJin Young KimDong-Gun LeeHoon-Gu KimHawk KimYoung-Don JooYoo Hong Min
- [9] Recombinant human interleukin-1 beta: new possibilities for the prophylaxis and correction of toxic myelodepression in patients with malignant tumors I. Phase I-II clinical trials of recombinant human interleukin-1 beta as a leukopoiesis stimulator in cancer patients receiving combination chemotherapyEUROPEAN CYTOKINE NETWORK, 2001, 12 (04) : 664 - 670Gershanovich, MLFilatova, LVKetlinsky, SASimbirtsev, AS